You are here

FDA Approves Generic Synthroid Tablets

PITTSBURGH, June 24 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Levothyroxine Sodium Tablets in 0.025 mg, 0.050 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.15 mg, 0.175 mg, 0.2 mg and 0.3 mg strengths.

Levothyroxine Sodium Tablets are the generic version of Abbott Laboratories' Synthroid(R) Tablets.

"We are very pleased with this product approval," stated Robert J. Coury, Mylan's Vice Chairman and CEO. "This approval represents a very important addition to our product portfolio and finally brings closure to some of the tactics used by others to delay legitimate generic approvals."

The product will be shipped immediately.

Source: Mylan Laboratories, Inc.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key